STAT News

SEPTEMBER 6, 2022

WASHINGTON — Researchers studying next-generation vaccines to fight an evolving Covid-19 threat are running into problems getting existing vaccines to use in their research. Right now, Pfizer isn’t sharing its vaccines for research purposes, a spokesperson confirmed to STAT.

Vaccination 145

Vaccination Vaccine Research Production 145

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

RNA 345

RNA Vaccination Vaccine Trials 345

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 13, 2024

The Subject Expert Committee (SEC), which advises the Central drug regulator regarding clinical trials and approvals of drugs, has recommended approval for additional indication of Zydus Lifesciences’ inactivated trivalent influenza vaccine in children above six months with clinical trial waiver subject to condition.

Vaccination 148

Vaccination Vaccine Clinical Trials Clinical Trials 148

Drug Discovery World

MARCH 13, 2024

UK researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to evolve. The researchers found that both vaccines generated neutralising antibodies against the most recent strain of Omicron, BA.2.86.

Vaccination 52

Vaccination Vaccine Research Antibody 52

Pharmaceutical Technology

APRIL 14, 2023

Ghana’s Food and Drug Authority (FDA) has approved R21/Matrix-M malaria vaccine in children aged 5 to 36 months, marking the first regulatory clearance for the University of Oxford-developed vaccine in any country in the world. Children between the ages of five and 36 months are at highest risk of death from malaria.

Vaccination 279

Vaccination Vaccine Manufacturing Containment 279

Bio Pharma Dive

APRIL 9, 2021

The EMA has reiterated the benefits of the shot outweigh the risks, but the safety concerns are another hurdle to the vaccine's rollout in Europe.

Vaccination 312

Vaccination Vaccine Research 312

Bio Pharma Dive

FEBRUARY 21, 2024

The Danish company scrapped a vaccine in Phase 1 testing and will exit oncology altogether, focusing instead on infectious disease research.

Vaccination 183

Vaccination Vaccine Research 183

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 11, 2024

Using viruses that infect bacteria to detect proteins sprouted by a notorious parasite, scientists have honed in on possible vaccine targets for schistosomiasis, a neglected tropical disease that currently affects an estimated 600 million people worldwide, causing 280,000 deaths per year.

Vaccination 179

Vaccination Vaccine Bacteria Protein 179

pharmaphorum

SEPTEMBER 18, 2023

US researchers start trials of universal flu vaccine Phil.Taylor Mon, 18/09/2023 - 09:20 Bookmark this

Vaccination 111

Vaccination Vaccine Trials Research 111

Rethinking Clinical Trials

AUGUST 22, 2023

In an article published this month in Clinical Trials , researchers from the NIH Pragmatic Trials Collaboratory’s Distributed Research Network share opportunities for conducting pragmatic trials embedded in health insurance plans. For more, see the Distributed Research Network page on the Living Textbook or read the full article.

Research 245

Research Clinical Trials Clinical Trials Trials 245

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 22, 2024

The Indian Institute of Science (IISc) is now developing a heat-tolerant vaccine that can offer protection against different strains of SARS-CoV-2 – both current and future variants. The research […]

Vaccination 149

Vaccination Vaccine Development Research 149

Pharmaceutical Technology

JUNE 6, 2023

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. The project is a partnership with Inspirevax and the National Research Council of Canada (NRC).

Vaccination 231

Vaccination Vaccine Development Manufacturing 231

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 12, 2024

That’s how many vaccines a man in Germany claims to have received for COVID-19 in just 29 months – and his body isn’t reacting the way some scientists thought it would. Two hundred and seventeen. The 62-year-old male from the city of Magdeburg made headlines a few years ago for his private and risky decision […]

Scientist 221

Scientist Vaccination Vaccine Clinical Trials 221

Drug Discovery World

MAY 13, 2024

Reece Armstrong speaks to Melanie Adams-Cioaba , Senior Director and General Manager of pharma (cryo-EM), Thermo Fisher Scientific about advances in vaccine design. Using structural biology as central to vaccine design and development, and to drug discovery more generally, is what we mean by “rational design.”

Vaccination 59

Vaccination Vaccine Protein Antibody 59

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccination 245

Vaccination Vaccine Development Allergies 245

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 3, 2023

An experimental vaccine that aims to slow down or prevent the progression of Alzheimer’s disease has been trialed in mice with promising early results. Mice engineered with genes that put them at greater risk of an Alzheimer’s-like disease had fewer amyloid plaques following the vaccine.

Vaccination 235

Vaccination Vaccine Engineer Gene 235

Drug Discovery World

MAY 15, 2024

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. Building protective vaccines before a pandemic emerges “We don’t have to wait for new coronaviruses to emerge.

Vaccination 52

Vaccination Vaccine Immune Response Clinical Trials 52

Pharmaceutical Technology

JULY 1, 2022

Some months after the first Covid-19 vaccines became available, the World Health Organization (WHO) set a target of vaccinating 70% of each country’s population by the end of June 2022. The post Magazine-How delays derailed Covid-19 vaccination in Africa appeared first on Pharmaceutical Technology.

Vaccination 277

Vaccination Vaccine Big Data Development 277

Bio Pharma Dive

DECEMBER 18, 2023

The newly established initiative, which consists of a research center and an accelerator, will focus on developing vaccines for tuberculosis, influenza and group A streptococcus.

Vaccination 152

Vaccination Vaccine Development Research 152

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 8, 2023

The World Health Organization has approved a new vaccine that scientists argue will be a game-changer in the fight against malaria, which kills half a million people in Africa every year.

Vaccination 215

Vaccination Vaccine Scientist Trials 215

Medical Xpress

MAY 1, 2023

People who refused to get vaccinated against COVID-19 had low levels of social trust, weak attachments to the rule of law, and were less willing to honor collective commitments to the greater good, according to Cornell research published April 22 in npj Vaccines.

Vaccination 98

Vaccination Vaccine Research 98

Pharma Mirror

APRIL 24, 2022

and NEC Corporation, today announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic vaccine. NEC OncoImmunity, an NEC subsidiary that specializes in artificial intelligence-driven biotechnology, is also participating in this research collaboration.

Vaccination 130

Vaccination Vaccine Research Development 130

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science 246

Life Science Vaccination Vaccine Development 246

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 28, 2023

India’s success story in pediatric vaccination programme should be further replicated in the form of adult vaccination programme, experts recommended on the occasion of the 2nd edition of the India Vaccine Leaders Conclave (IVLC) held between August 22 and August 23, 2023 under the theme “Building Resilient Vaccine Ecosystems” in Mumbai.

Vaccination 161

Vaccination Vaccine Clinical Trials Clinical Trials 161

Pharmaceutical Technology

DECEMBER 5, 2022

Sanofi has signed an agreement with the Queensland Government in Australia to establish a $190m (A$280m) research facility in Brisbane. With the establishment of this Translational Science Hub, Queensland is set to become an international messenger ribonucleic acid (mRNA) vaccine hub.

Research 246

Research Gene Therapy Vaccination Vaccine 246

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 22, 2022

The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB). The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells.

Vaccination 100

Vaccination Vaccine Research Bacteria 100

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

Drug Discovery World

OCTOBER 24, 2023

The DDW Turning Science into Business Summit, ‘ Cancer research opportunities and advances ’ will take place online on 16 November at 7AM PST / 10AM EDT / 3PM GMT / 4PM CET. This free summit, sponsored by Taconic, will offer expert thought leadership on cancer research, precision medicine and immunotherapy.

Vaccination 52

Vaccination Vaccine Research Clinical Development 52

Velocity Clinical Research

SEPTEMBER 14, 2023

Velocity has introduced the Vaccine Council to Accelerate Research Excellence (CARE). This council will bring world-class operational, patient recruitment, and trial conduct oversight to all Velocity sites conducting vaccine studies in the U.S. and Europe.

Vaccination 52

Vaccination Vaccine Research Clinical Research 52

Drug Discovery World

MAY 1, 2024

The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. seed financing appeared first on Drug Discovery World (DDW).

Vaccination 59

Vaccination Vaccine Development Clinical Trials 59

Scienmag

JULY 8, 2022

ATLANTA—A new universal flu vaccine protects against influenza B viruses, offering broad defense against different strains and improved immune protection, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

Vaccination 94

Vaccination Vaccine Research Medicine 94

Scienmag

JANUARY 28, 2022

ATLANTA—An influenza vaccine administered through the nose and constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

Immune Response 95

Immune Response Vaccination Vaccine Research 95

Scienmag

JANUARY 6, 2021

Funding for device that gives vaccine and monitors response Credit: IMPACT, Swansea University Researchers at Swansea University have received £230,000 to develop the world’s first smart vaccine device that will both deliver the COVID-19 vaccine and measure its efficacy through monitoring the body’s associated response.

Vaccination 94

Vaccination Vaccine Research Development 94

XTalks

FEBRUARY 19, 2024

Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Medical Xpress

APRIL 7, 2023

After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists are turning their attention to utilizing this innovative technology to ward off other infectious diseases like malaria and influenza.

Vaccination 85

Vaccination Vaccine Development Research 85